Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Unknown 13Recruiting 8Not yet recruiting 3Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 22Gastrointestinal 8Head & Neck 5Sarcoma 3Gynecologic 3Breast 3Tumor-Agnostic 2Genitourinary 2Endocrine 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16trastuzumab deruxtecan 15Docetaxel 15Radiotherapy 13Standard of Care 12Fulvestrant 12Drug Therapy 12dalpiciclib 11Letrozole 11pembrolizumab 9Epirubicin 9sacituzumab govitecan 8palbociclib 8exemestane 8eribulin 8Anastrozole 8Injections 7Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Specimen Handling 6Neoadjuvant Therapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × anlotinib × Breast × Clear all
NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 1/2 Not yet recruiting
59 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06605690 2024-09-20

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

The Affiliated Hospital Of Guizhou Medical University

Phase NA Not yet recruiting
30 enrolled
Breast

Breast Neoplasms

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡